UCB Reports Results of Bimekizumab in P-III BE SURE Study for Moderate-To-Severe Chronic Plaque Psoriasis

 UCB Reports Results of Bimekizumab in P-III BE SURE Study for Moderate-To-Severe Chronic Plaque Psoriasis

UCB’s Nayzilam (midazolam) Receives FDA’s Approval for the Treatment of Seizure Cluster in Epilepsy in the US

Shots:

  • The P-III BE SURE study involves assessing bimekizumab vs AbbVie’s Humira (adalimumab) in 478 patients with chronic PSO for at least 6mos. prior to screening with an affected body SA of at least 10%, PASI of at least 12 and IGA score ≥3
  • The P-III BE SURE study result: met its co-1EPs @16wks. ie, 90% improvement in PASI 90 and IGA score of clear or almost clear (IGA 0/1); met its 2EPs, skin clearance @16 &24wks. & rapid response @4wks. measured by PASI 100 & PASI 75
  • Bimekizumab is an investigational IgG1 mAb targeting L-17A and IL-17F with its anticipated regulatory submission in mid-2020

Click here to­ read full press release/ article | Ref: PRNewswire | Image: UCB

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post